Rheacell GmbH & Co. KG
- Address
- Im Neuenheimer Feld 517, Neuenheim
Sponsor Overview
Specializations
Inherited skin blistering disorders
Rheacell GmbH & Co. KG focuses on clinical research in epidermolysis bullosa, with attention to both recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa. The sponsor’s work in this area is centered on severe skin fragility, chronic wound burden, and the need for therapies that support wound improvement in affected patients.
- Recessive dystrophic epidermolysis bullosa
- Junctional epidermolysis bullosa
- Wound healing
Clinical activity in this field includes both adult and very young patients, reflecting interest in difficult-to-treat inherited skin disease across age groups.
Chronic venous ulcer care
The company also conducts research in chronic venous ulcers, including therapy-resistant and long-term non-healing lesions. This therapeutic area highlights a strong focus on persistent lower-limb wound disease, where closure of chronic ulcers remains a central clinical goal.
- Chronic venous ulcers
- Non-healing venous leg ulcers
- Ulcer closure
Its studies in this domain address patients with wounds that have not responded adequately to standard care, underscoring interest in advanced wound management.
Cell-based and regenerative therapies
Rheacell’s trial portfolio includes investigations involving stem cell and mesenchymal cell therapies for dermatologic and wound-related conditions. This indicates an emphasis on regenerative approaches aimed at restoring tissue integrity and supporting repair in chronic skin injury.
- Stem cell therapy
- Mesenchymal stromal cells
- Regenerative wound treatment
These activities connect cellular medicine with unmet needs in inherited blistering disease and chronic ulceration.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A double-blind, randomized, placebo-controlled, interventional, multicenter, phase III clinical trial to investigate the safety and efficacy of ABCB5-positive mesenchymal stromal cells (ABCB5+ MSCs) on epidermolysis bullosa (EB) |  Austria Croatia Denmark France Germany Greece Hungary Italy Poland Portugal Spain The Netherlands | Not Yet Recruiting |
| Efficacy and Safety Evaluation of Allogeneic Skin-Derived ABCB5-Positive Dermal Mesenchymal Stromal Cells in Therapy-Resistant Chronic Venous Ulcers | Germany | Not Recruiting |
| Efficacy and Safety of Allogeneic Skin-Derived ABCB5-Positive Dermal Mesenchymal Stromal Cells in Therapy-Resistant Chronic Venous Ulcers | Austria Czechia France Germany Hungary Italy Poland Slovakia Sweden The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 16 molecules, of which 2 are not being studied by other sponsors.
This sponsor has worked with 93 sites across their trial portfolio.
Therapeutic Focus
- 1.Skin and Connective Tissue Diseases3 trials247 other sponsors
- 2.Congenital, Hereditary, and Neonatal Diseases and Abnormalities1 trial166 other sponsors
Partnered Research Centres
93 centres- Address
- Dragoumi Ionos 5 I, 161 21 Athens
- Address
- Prostejovská 125, 080 01 Prešov
- Address
- Ružová 277, 929 01 Dunajská Streda
- Address
- Novosadska 4, 917 01 Trnava
- Address
- Sterlinga 27/29, 90-212 Lodz
- Address
- Viale Mazzini (Ex Ospedale Umberto I), 03100 Frosinone
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Rheacell GmbH & Co. KG.
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.